## CITATION REPORT List of articles citing

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial

DOI: 10.1016/s0140-6736(18)32321-3 Lancet, The, 2019, 393, 1517-1526.

**Source:** https://exaly.com/paper-pdf/73510057/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 75 | Analysis of the RIMDAMAL trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1005-1006  | 40   | 5         |
| 74 | The effect of food on the pharmacokinetics of oral ivermectin. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 438-440  | 5.1  | 1         |
| 73 | Reducing malaria burden and accelerating elimination with long-lasting systemic insecticides: a modelling study of three potential use cases. <i>Malaria Journal</i> , <b>2019</b> , 18, 307   | 3.6  | 1         |
| 72 | Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?. <i>Infectious Diseases of Poverty</i> , <b>2019</b> , 8, 77   | 10.4 | 2         |
| 71 | Malaria eradication within a generation: ambitious, achievable, and necessary. <i>Lancet, The</i> , <b>2019</b> , 394, 1056-1112   | 40   | 130       |
| 70 | Analysis of the RIMDAMAL trial - Authors Vreply. Lancet, The, 2019, 394, 1006-1007   | 40   | 4         |
| 69 | Analysis of the RIMDAMAL trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1006   | 40   | 1         |
| 68 | Viral Appropriation: Laying Claim to Host Nuclear Transport Machinery. Cells, 2019, 8,   | 7.9  | 12        |
| 67 | Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. <i>Lancet, The</i> , <b>2019</b> , 393, 1517-1526   | 40   | 56        |
| 66 | Advancing the repurposing of ivermectin for malaria. <i>Lancet, The</i> , <b>2019</b> , 393, 1480-1481   | 40   | 9         |
| 65 | Inhibition of Plasmodium sporogonic stages by ivermectin and other avermectins. <i>Parasites and Vectors</i> , <b>2019</b> , 12, 549   | 4    | 9         |
| 64 | Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1221-1230 | 6.1  | 17        |
| 63 | Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 498-508   | 25.5 | 20        |
| 62 | Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. <i>Tropical Medicine and International Health</i> , <b>2020</b> , 25, 380-386  | 2.3  | 11        |
| 61 | Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,                      | 5.9  | 4         |
| 60 | Repurposing Drugs to Fight Hepatic Malaria Parasites. <i>Molecules</i> , <b>2020</b> , 25,   | 4.8  | 7         |
| 59 | House modifications for preventing malaria. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD013398   | 5.2  | 8         |

## (2021-2020)

| 58 | Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. <i>Pharmaceuticals</i> , <b>2020</b> , 13,   | 5.2  | 25 |
|----|--|------|----|
| 57 | A Model for Assessing the Quantitative Effects of Heterogeneous Affinity in Malaria Transmission along with Ivermectin Mass Administration. <i>Applied Sciences (Switzerland)</i> , <b>2020</b> , 10, 8696   | 2.6  | 2  |
| 56 | Malaria transmission-blocking drugs: implications and future perspectives. <i>Future Medicinal Chemistry</i> , <b>2020</b> , 12, 1071-1101   | 4.1  | 2  |
| 55 | Epidemiology and risk factors of Strongyloides stercoralis infection in Papua, Indonesia: a molecular diagnostic study. <i>Acta Tropica</i> , <b>2020</b> , 209, 105575  | 3.2  | O  |
| 54 | Power calculations for cluster randomized trials (CRTs) with right-truncated Poisson-distributed outcomes: a motivating example from a malaria vector control trial. <i>International Journal of Epidemiology</i> , <b>2020</b> , 49, 954-962  | 7.8  | 5  |
| 53 | Toward the Definition of Efficacy and Safety Criteria for Advancing Gene Drive-Modified Mosquitoes to Field Testing. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2020</b> , 20, 237-251   | 2.4  | 30 |
| 52 | Vitamin E and selenium administration synergistically mitigates ivermectin and doramectin-induced testicular dysfunction in male Wistar albino rats. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 124, 109841  | 7.5  | 11 |
| 51 | Evidence of extrinsic factors dominating intrinsic blood host preferences of major African malaria vectors. <i>Scientific Reports</i> , <b>2020</b> , 10, 741  | 4.9  | 7  |
| 50 | Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1361-1373 | 40   | 30 |
| 49 | Effects of combined drug treatments on Plasmodium falciparum: In vitro assays with doxycycline, ivermectin and efflux pump inhibitors. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232171  | 3.7  | 1  |
| 48 | Ivermectin, a potential anticancer drug derived from an antiparasitic drug. <i>Pharmacological Research</i> , <b>2021</b> , 163, 105207  | 10.2 | 22 |
| 47 | Identification of the metabolites of ivermectin in humans. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00712   | 3.1  | 8  |
| 46 | Chemotherapy of Malaria and Other Protozoal Diseases. <b>2021</b> , 973-1026   |      |    |
| 45 | Ivermectin in the treatment of COVID-19- friend or foe?. South African General Practitioner, 2021, 2, 15-  | 18.1 | O  |
| 44 | A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. <i>PLoS Neglected Tropical Diseases</i> , <b>2021</b> , 15, e0009144  | 4.8  | 10 |
| 43 | Sample size and power considerations for cluster randomized trials with count outcomes subject to right truncation. <i>Biometrical Journal</i> , <b>2021</b> , 63, 1052-1071   | 1.5  | 1  |
| 42 | Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action. <i>Molecules</i> , <b>2021</b> , 26,   | 4.8  | 6  |
| 41 | The role and challenges of cluster randomised trials for global health. <i>The Lancet Global Health</i> , <b>2021</b> , 9, e701-e710   | 13.6 | 12 |

Ivermectin treatment in humans for reducing malaria transmission. *The Cochrane Library*, **2021**, 6, CD0134.17 40 Ivermectin: A Promising Therapeutic for Fighting Malaria. Current Status and Perspective. Journal 8.3 39 of Medicinal Chemistry, **2021**, 64, 9711-9731 Broadening the range of use cases for ivermectin - a review of the evidence. Transactions of the 38  $\circ$ Royal Society of Tropical Medicine and Hygiene, 2021, Anopheles bionomics in a malaria endemic area of southern Thailand. Parasites and Vectors, 2021, 37 14, 378 Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. 36 2.2 1 Clinical Trials, 2021, 18, 582-593 Ingestible devices for long-term gastrointestinal residency: a review. Progress in Biomedical 35 7.2 Engineering, **2021**, 3, 042001 The use of barcoded Asaia bacteria in mosquito in vivo screens for identification of systemic 34 insecticides and inhibitors of malaria transmission. House modifications for preventing malaria. The Cochrane Library, 2021, 1, CD013398 33 5.2 Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control 32 7 Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial. JMIR Research Protocols. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. 28 31 3.2 American Journal of Tropical Medicine and Hygiene, 2020, 102, 3-24 The vectors of Plasmodium knowlesi and other simian malarias Southeast Asia: challenges in 30 3.2 5 malaria elimination. Advances in Parasitology, 2021, 113, 131-189 Antiprotozoal agents: How have they changed over a decade?. Archiv Der Pharmazie, 2021, e2100338 29 4.3 Insecticide-treated livestock: a potential One Health approach to malaria control in Africa. Trends in 28 6.4 О Parasitology, 2021, The use of islands and cluster-randomized trials to investigate vector control interventions: a case study on the Bijaglarchipelago, Guinea-Bissau. Philosophical Transactions of the Royal Society B: 5.8 27 *Biological Sciences*, **2021**, 376, 20190807 Ivermectin and Moxidectin Can Incapacitate Different Strains of the Common Bed Bug Cimex 26 1.2 lectularius L.: A Study. Cureus, 2020, 12, e6714 Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin 25 and chloroquine in Rhesus Macagues. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatology Online 24 0.9 Journal, 2021, 12, 500-514 Current use of ivermectin in dermatology, tropical medicine, and COVID-19: An update on pharmacology, uses, proven and varied proposed mechanistic action. Indian Dermatology Online 23 Journal, **2021**, 12, 500

| 22 | Ignoring transmission dynamics leads to underestimation of the impact of a novel intervention against mosquito-borne disease.  |        | 0  |
|----|--|--------|----|
| 21 | Potential impact of 5 years of ivermectin mass drug administration on malaria outcomes in high burden countries. <i>BMJ Global Health</i> , <b>2021</b> , 6,   | 6.6    |    |
| 20 | Ivermectin as an endectocide may boost control of malaria vectors in India and contribute to elimination <i>Parasites and Vectors</i> , <b>2022</b> , 15, 20   | 4      | 2  |
| 19 | and effectiveness of three insecticides types for eradication of the tick in dogs <i>Open Veterinary Journal</i> , <b>2022</b> , 12, 44-60   | 1      |    |
| 18 | Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , | 25.5   | 4  |
| 17 | Barcoded Asaia bacteria enable mosquito in vivo screens and identify novel systemic insecticides and inhibitors of malaria transmission <i>PLoS Biology</i> , <b>2021</b> , 19, e3001426   | 9.7    | Ο  |
| 16 | A six-months, long acting, one-shot injectable formulation of Ivermectin as a complementary malaria vector control tool to target zoophagic Anopheles: laboratory and model-based proofs of concept.   |        |    |
| 15 | Ivermectin and curcumin cause plasma membrane rigidity in Leishmania amazonensis due to oxidative stress. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>2022</b> , 1864, 183977   | 3.8    |    |
| 14 | Drug development for onchocerciasis-the past, the present and the future. <i>Frontiers in Tropical Diseases</i> , 3,   |        |    |
| 13 | Repeat Ivermectin Mass Drug Administrations for Malaria Control II: a double-blind, cluster-randomized control trial for integrated control of malaria. Protocol for the RIMDAMAL II Trial (Preprint).   |        |    |
| 12 | Back to the Future: Quantifying Wing Wear as a Method to Measure Mosquito Age. 2022,   |        | О  |
| 11 | Ivermectin Poisoning with Neurological Manifestations in 10 Years Old Girl 🛭 Case Report. <b>2022,</b> 9, 87-89  |        | O  |
| 10 | Proof-of-concept study for a long-acting formulation of ivermectin injected to cattle as a complementary malaria vector control tool.  |        | 0  |
| 9  | House modifications for preventing malaria. <b>2022</b> , 2022,  |        | O  |
| 8  | Conservation of Importin Function in Apicomplexans: Ivermectin and GW5074 Target Plasmodium falciparum Importin and Inhibit Parasite Growth in Culture. <b>2022</b> , 23, 13899  |        | O  |
| 7  | Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial. <b>2022</b> , 15,   |        | О  |
| 6  | Effect of Ivermectin on survivorship and fertility of Anopheles arabiensis in Ethiopia: an in vitro study. <b>2023</b> , 22,   |        | 0  |
| 5  | Striving towards true equity in global health: A checklist for bilateral research partnerships. <b>2023</b> , 3, e0  | 000141 | 80 |

| 4 | Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool. <b>2023</b> , 16,   | 0 |
|---|---|---|
| 3 | Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. 12, e41197   | O |
| 2 | BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africall phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. <b>2023</b> , 24, | О |
| 1 | A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.   | O |